An experimental version of the Alzheimer’s drug Lekembi that can be taken at home has been found to be more effective than the form of the drug given intravenously in a hospital setting. This is reported on the company’s website Eisai.
Lekembi is the first drug that can significantly slow the progression of Alzheimer’s disease. It currently needs to be given intravenously every two weeks in hospital, which may be an obstacle to its widespread use. In a new study, scientists from the pharmaceutical company Eisai compared the treatment results of 72 patients who received injections of the new drug for home use and 322 patients who received the traditional version for intravenous administration.
After six months of treatment, the new form of the drug eliminated 14% more amyloid, a toxic protein associated with Alzheimer’s disease, than the existing drug. The incidence of the main side effects, brain swelling and bleeding, was the same in both versions.
Even with the new injectable version, Lekembi treatment requires a PET scan of the brain to detect amyloid and an MRI scan to monitor side effects. However, the new form of the drug will help its use become widespread because it requires fewer hospital visits.
Brain electrode before delivered A woman wanting to wash herself after cleaning the tray.